Lack of reliability of nanotechnology in the of free plasma DNA in samples of patients with prostate cancer.

Autor: Moreno R; Laboratório de Análises Clínicas, Faculdade de Medicina do ABC, Av, Príncipe de Gales 821, Santo André, CEP: 09060-650, Brazil. fon_fonseca@yahoo.com.br., Delgado PO, Coelho PG, Marsicano SR, Boas VA, Azzalis LA, Junqueira VB, Rocha KC, de Abreu LC, Valenti VE, Drezzet J, Pereira EC, Fonseca FL
Jazyk: angličtina
Zdroj: International archives of medicine [Int Arch Med] 2013 Jan 12; Vol. 6 (1), pp. 2. Date of Electronic Publication: 2013 Jan 12.
DOI: 10.1186/1755-7682-6-2
Abstrakt: Background: Several studies seek biological markers that give diagnostic and degree of tumor development. The aim of this study was to validate the determination of plasma DNA using nanotechnology (Nanovue™-NV) in samples of 80 patients with prostate cancer.
Methods: Blood samples of 80 patients of the Urology Ambulatory of Faculdade de Medicina do ABC with prostate cancer confirmed by anatomical-pathology criteria were analyzed. DNA extraction was performed using a GFX TM kit (Amersham Pharmacia Biotech, Inc, USA) following the adapted protocol. Plasma was subjected to centrifugation.
Results: There was a big difference between the first and the second value obtained by NanoVue Only two samples had no differences between duplicates. Maximum difference between duplicates was 38 μg/mL. Average variation between 51 samples was 10.29 μg/mL, although 21 samples had differences above this average. No correlation was observed between pDNA obtained by traditional spectrophotometry and by nanotechnology.
Conclusion: Determination of plasma DNA by nanotechnology was not reproducible.
Databáze: MEDLINE
Externí odkaz: